To include your compound in the COVID-19 Resource Center, submit it here.

NewLink reports updated Phase II data for IDO/PD-1 combo in melanoma

NewLink Genetics Corp. (NASDAQ:NLNK) reported updated response data from 51 evaluable patients with cutaneous, mucosal or melanoma of unknown primary origin in the Phase II portion of the Phase Ib/II NLG2103

Read the full 316 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE